← Eichor
Study identifier: NCT07512960 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization

Condition: CLTI Defined as Rutherford Category 4 or 5  ·  Sponsor: Fondation Hôpital Saint-Joseph

PhasePhase 3
Planned participants614
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

Chronic limb threatening ischemia (CLTI) is defined as ischemic foot pain at rest or non-healing foot wounds that is attributable to severe peripheral arterial disease (PAD).Revascularization is the cornerstone of therapy to relieve ischemic pain, prevent limb loss and preserve patient autonomy. Revascularization procedures often involve below-the-knee arterial disease in CLTI population. Dual antiplatelet therapy (DAPT, with aspirin, and clopidogrel) is recommended for at least 1-month after peripheral angioplasty. However, the exact duration of this DAPT remains controversial. Angioplasty of below-the-knee arteries is often followed by a longer period of DAPT, 3-months to one-year, due to a high risk of arterial thrombosis/stenosis.It will be the first trial on duration of DAPT in patients with below-the-knee angioplasty for CLTI, the end-stage of PAD

This description comes directly from the study's public registry record.

Talk to the study team

Joseph Emmerich, Pr  ·  +33 1 44 12 37 64  ·  jemmerich@ghpsj.fr

Naima SGHIOUAR, PhD  ·  +330144123362  ·  nsghiouar@ghpsj.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Saint JosephParis, Île-de-France Region, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07512960